Top Markets
Coin of the day
Kineta, Inc. Kineta, Inc.

Kineta, Inc.

KA
Rank in Stocks #34153
Kineta, Inc. is a clinical-stage biotechnology firm dedicated to developing... Kineta, Inc. is a clinical-stage biotechnology firm dedicated to developing immunotherapies, with a focus on oncology, neuroscience, and biodefense applications. The company engages in partnerships with a variety of entities, including private companies, government bodies, and other industry stakeholders. Among its significant strategic collaborators are Pfizer, Genentech, Wellcome, and Samsung Biologics Co., Ltd. Established in 2007, Kineta, Inc. was previously known as Lecura, Inc. and has its base of operations in Seattle, Washington.
Share Price
$0.617
Last synced: 2024-10-14
Market Cap
$6.13M
Change (1 day)
0.49%
Change (1 year)
0.00%
Country
US
Trade Kineta, Inc. (KA)

Category

Operating Margin for Kineta, Inc. (KA)
Operating Margin as of August 2026 TTM: 0.00%
According to Kineta, Inc. latest financial reports and stock price the company's current Operating Margin (TTM) is 0.00%. At the end of 2023 the company had an Operating Margin of -288.92%.
Operating Margin history for Kineta, Inc. from 2015 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
2026 (TTM) 0.00% -100.00%
2024 0.00% -100.00%
2023 -288.92% -86.41%
2022 -2,126.52% 1,642.76%
2021 -122.02% 310.84%
2020 -29.70% -97.57%
2019 -1,223.08% -45.02%
2018 -2,224.72% 98.13%
2017 -1,122.88% 151.35%
2016 -446.74% -21.48%
2015 -568.97% 0.00%
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
38.59% -
US
28.81% -
NL
0.00% -
CH
0.00% -
KR
31.23% -
BE
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.